Litcius/Paper detail

Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: The SAMCO-PRODIGE 54 randomised phase II trial

Julien Taı̈eb, Thierry André, Farid El Hajbi, Emilie Barbier, Clémence Toullec, Stéfano Kim, Olivier Bouché, Frédéric Di Fiore, Marion Chauvenet, Hervé Perrier, Ludovic Evesque, Pierre Laurent‐Puig, Jean‐François Emile, Jérémie Bez, Côme Lepage, David Tougeron

2020Digestive and Liver Disease26 citationsDOI

Topics & Concepts

AvelumabMedicineOncologyColorectal cancerInternal medicineRegimenMicrosatellite instabilityPopulationChemotherapyChemotherapy regimenCancerNivolumabImmunotherapyChemistryEnvironmental healthMicrosatelliteAlleleGeneBiochemistryCancer Immunotherapy and BiomarkersColorectal Cancer Treatments and StudiesGenetic factors in colorectal cancer
Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: The SAMCO-PRODIGE 54 randomised phase II trial | Litcius